Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 07/10/25
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 CongressPRNewsWire • 06/24/25
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?Zacks Investment Research • 05/28/25
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYBusiness Wire • 05/21/25
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy BizZacks Investment Research • 05/19/25
How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit GainInvestors Business Daily • 05/16/25
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology MeetingsPRNewsWire • 05/12/25
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/02/25
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/01/25
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ETPRNewsWire • 04/17/25
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/16/25
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic VolatilityThe Motley Fool • 04/11/25
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?Zacks Investment Research • 04/10/25
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely OnZacks Investment Research • 04/09/25
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)Zacks Investment Research • 04/07/25